Core Viewpoint - The company, Baolingbao (002286), has recently obtained a "Drug Production License" from the Shandong Provincial Drug Administration, which allows it to produce the raw material drug lactulose solution, marking the beginning of its diversification into raw material drugs [1] Group 1 - The acquisition of the "Drug Production License" accelerates the subsequent application, registration, and market launch processes for the company's first raw material drug, lactulose [1] - This license represents a significant step in the company's strategy to diversify its raw material drug offerings [1]

Core Viewpoint - The company has obtained a Drug Manufacturing License from the Shandong Provincial Drug Administration, which accelerates the registration and market launch process for its first active pharmaceutical ingredient, lactulose solution, marking the beginning of its diversification in the active pharmaceutical ingredient sector [1] Group 1 - The Drug Manufacturing License was issued for the production site located at No. 1, East Outer Ring Road, Yucheng, High-tech Industrial Development Zone, Dezhou, Shandong [1] - The license specifically pertains to the active pharmaceutical ingredient lactulose solution, which is limited to registered declaration use [1] - The acquisition of this license is a significant step for the company in expanding its portfolio of active pharmaceutical ingredients [1]